Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Allogene Therapeutics, Inc. reported revenue of $0M, down 100.0% year over year. Operating margin was n/a and net margin n/a, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from ALLO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | n/a | n/a |
| FY2024 | $0M | -1241813.6% | -1170863.6% |
| FY2023 | $0M | -344986.3% | -344489.5% |
| FY2022 | $0M | -215087.2% | -218214.1% |
| FY2021 | $114M | -157.9% | -159.6% |
How does ALLO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.